Proliferative effects of insulin analogues on mammary epithelial cells - PubMed (original) (raw)

Review

Proliferative effects of insulin analogues on mammary epithelial cells

Doris Mayer et al. Arch Physiol Biochem. 2008 Feb.

Abstract

Structural modification of insulin results in the generation of insulin analogues that show altered binding affinities to the insulin receptor and/or IGF-I receptor. As a consequence these insulin analogues may have increased mitogenic potency. Nine benign or malignant human mammary epithelial cells, which show different insulin receptor and IGF-I receptor expression patterns, were studied regarding mitogenicity of insulin and insulin analogues. Only insulin glargine showed a significantly higher proliferative effect on MCF-7 breast cancer cells compared to regular insulin among a panel of short- or long-acting insulin analogues, that are in clinical use.

PubMed Disclaimer

Similar articles

• Proliferative effect of Apidra (insulin glulisine), a rapid-acting insulin analogue on mammary epithelial cells.
  Shukla A, Enzmann H, Mayer D. Shukla A, et al. Arch Physiol Biochem. 2009 Jul;115(3):119-26. doi: 10.1080/13813450903008628. Arch Physiol Biochem. 2009. PMID: 19480564
• Alternative signaling network activation through different insulin receptor family members caused by pro-mitogenic antidiabetic insulin analogues in human mammary epithelial cells.
  ter Braak B, Wink S, Koedoot E, Pont C, Siezen C, van der Laan JW, van de Water B. ter Braak B, et al. Breast Cancer Res. 2015 Jul 19;17(1):97. doi: 10.1186/s13058-015-0600-5. Breast Cancer Res. 2015. PMID: 26187749 Free PMC article.
• Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells.
  Staiger K, Hennige AM, Staiger H, Häring HU, Kellerer M. Staiger K, et al. Horm Metab Res. 2007 Jan;39(1):65-7. doi: 10.1055/s-2007-957352. Horm Metab Res. 2007. PMID: 17226117 No abstract available.
• Growth effects of insulin and insulin analogues.
  Sandow J. Sandow J. Arch Physiol Biochem. 2009 May;115(2):72-85. doi: 10.1080/13813450902835690. Arch Physiol Biochem. 2009. PMID: 19485703 Review.
• Mitogenic potency of insulin glargine.
  Zełobowska K, Gumprecht J, Grzeszczak W. Zełobowska K, et al. Endokrynol Pol. 2009 Jan-Feb;60(1):34-9. Endokrynol Pol. 2009. PMID: 19224503 Review.

Cited by

• The relationship between pancreatic cancer and type 2 diabetes: cause and consequence.
  Li Y, Bian X, Wei S, He M, Yang Y. Li Y, et al. Cancer Manag Res. 2019 Sep 9;11:8257-8268. doi: 10.2147/CMAR.S211972. eCollection 2019. Cancer Manag Res. 2019. PMID: 31571983 Free PMC article. Review.
• Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden.
  Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdòttir S, Steineck G. Jonasson JM, et al. Diabetologia. 2009 Sep;52(9):1745-54. doi: 10.1007/s00125-009-1444-2. Epub 2009 Jul 9. Diabetologia. 2009. PMID: 19588120
• The metabolic and mitogenic properties of basal insulin analogues.
  Tennagels N, Werner U. Tennagels N, et al. Arch Physiol Biochem. 2013 Feb;119(1):1-14. doi: 10.3109/13813455.2012.754474. Arch Physiol Biochem. 2013. PMID: 23373726 Free PMC article. Review.
• Diabetes and pancreatic cancer.
  Muniraj T, Chari ST. Muniraj T, et al. Minerva Gastroenterol Dietol. 2012 Dec;58(4):331-45. Minerva Gastroenterol Dietol. 2012. PMID: 23207610 Free PMC article. Review.
• Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing?
  Klil-Drori AJ, Azoulay L, Pollak MN. Klil-Drori AJ, et al. Nat Rev Clin Oncol. 2017 Feb;14(2):85-99. doi: 10.1038/nrclinonc.2016.120. Epub 2016 Aug 9. Nat Rev Clin Oncol. 2017. PMID: 27502359 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Taylor & Francis

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program